
HIMS
Hims & Hers Health Inc. Class A
Company Overview
| Mkt Cap | $9.60B | Price | $27.91 |
| Volume | 21.68M | Change | -5.04% |
| P/E Ratio | 76.2 | Open | $28.57 |
| Revenue | $1.5B | Prev Close | $29.39 |
| Net Income | $126.0M | 52W Range | $13.74 - $70.43 |
| Div Yield | N/A | Target | $26.79 |
| Overall | 46 | Value | 20 |
| Quality | 60 | Technical | 60 |
No chart data available
About Hims & Hers Health Inc. Class A
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
Latest News
Freeport, Southwest, Hims & Hers Trending Among Analysts
Now Is the Time to Buy Hims & Hers Stock (HIMS), Says JPMorgan Chase
Eli Lilly (LLY) Expands Partnership with Hims & Hers
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Greenwich LifeSciences (GLSI) and Harmony Biosciences Holdings (HRMY)
Hims & Hers Stock Boosts on FDA Peptide Review, Leerink Analyst Calls Move a “Clear Positive”
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HIMS | $27.91 | -5.0% | 21.68M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Hims & Hers Health Inc. Class A Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW